The National Institute for Health and Care Excellence (NICE) has recommended Roche’s faricimab (Vabysmo) as a treatment option for two leading forms of sight loss. Faricimab, an eye injection, is recommended for adults with wet age-related macular degeneration (AMD) or diabetic macular oedema (DMO).
Clinical evidence shows the drug is effective in improving vision and reducing vision loss. Faricimab can be administered less frequently than other medicines currently available, allowed for an interval of up to 16 weeks between doses.
The drug was found to be just as effective as the more frequently dosed aflibercept, another eye injection drug used to treat AMD and DMO. Aflibercept is administered every eight weeks…
